Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 25;6(3):159-163.
doi: 10.1016/j.ijwd.2020.02.007. eCollection 2020 Jun.

Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa

Kevin T Savage  1 , Elena Gonzalez Brant  2 , Monica Rosales Santillan  3 , Peyton C Morss  4 , Prerna Salian  3 , Kelsey S Flood  5 , Martina L Porter  3 , Alexa B Kimball  3
Affiliations

Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa

Kevin T Savage et al. Int J Womens Dermatol. .

Erratum in

  • Erratum regarding previously published articles.
    [No authors listed] [No authors listed] Int J Womens Dermatol. 2021 Sep 28;7(5Part B):867. doi: 10.1016/j.ijwd.2021.09.013. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35028405 Free PMC article.

Abstract

Background: Methotrexate is an immunomodulatory therapy that may offer benefit to patients with hidradenitis suppurativa (HS). Despite its theoretical advantages, there is a paucity of available data regarding long-term methotrexate use in patients with HS.

Objective: This study aimed to assess whether methotrexate treatment leads to improvement in HS disease severity.

Methods: We conducted an institutional review board-approved, single-center, retrospective chart review of patients with HS who were treated with methotrexate between 2000 and 2018. Primary outcome measurements included the HS Physician's Global Assessment (HS PGA), Hurley staging, abscess count, fistula count, and inflammatory nodule count.

Results: A total of 29 patients were identified; 14 were excluded for reasons including never starting methotrexate and missing follow-up data. For remaining patients (n = 15), the average cumulative dose of methotrexate was 520.1 mg (range, 30-1665 mg) and the average length of treatment was 11.7 months (range, 1-38 months). Patients taking methotrexate as a primary therapy had a higher cumulative dose and length of treatment (520.13 mg; 14.6 months) compared with those taking biologics concomitantly (468.44 mg; 9.1 months). Patients using methotrexate as primary therapy demonstrated nonsignificant reductions in HS PGA, inflammatory nodule count, and abscess count. Patients on concomitant biologic therapy failed to demonstrate any change in HS PGA, inflammatory nodule count, and abscess count.

Limitations: Limitations of the study include its retrospective nature, small sample size, length of time on methotrexate between groups, and homogeneity of the patient population.

Conclusion: Methotrexate may represent an effective treatment option in older patients with lower body mass indices but fails to offer benefit in patients taking concurrent biologic therapy.

Keywords: Abscesses; Biologic agents; Hidradenitis suppurativa; Methotrexate; Treatment.

PubMed Disclaimer

References

    1. Barrea L., Fabbrocini G., Annunziata G., Muscogiuri G., Donnarumma M., Marasca C. Role of nutrition and adherence to the Mediterranean diet in the multidisciplinary approach of hidradenitis suppurativa: Evaluation of nutritional status and its association with severity of disease. Nutrients. 2019;11(1):57. - PMC - PubMed
    1. Cronstein B.N., Eberle M.A., Gruber H.E., Levin R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991;88(6):2441–2445. - PMC - PubMed
    1. Crowley E.L., O’Toole A., Gooderham M.J. Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections. SAGE Open Med Case Rep. 2018;6 2050313X18778723. - PMC - PubMed
    1. Davis S.A., Lin H.C., Balkrishnan R., Feldman S.R. Hidradenitis suppurativa management in the United States: an analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin Appendage Disord. 2015;1(2):65–73. - PMC - PubMed
    1. De Souza A., Solomon G.E., Strober B.E. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis. 2011;69(2):185–187. - PubMed